10 June 2020 - Speaking at a session on cell and gene therapies at BIO Digital on Monday, a top US FDA official discussed the impact of the coronavirus disease (COVID-19) pandemic on the agency’s work related to cell and gene therapies.

While the pandemic has not resulted in an increase in applications for gene therapies, Bryan said his office has been busy with an increase in interest in using cell therapies and intravenous immunoglobulin to treat COVID-19.

Read Regulatory Affairs Professional Society article